...
首页> 外文期刊>The pharmacogenomics journal >Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia
【24h】

Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia

机译:线粒体超氧化物歧化酶(SOD2)和天冬酰胺酶的表达和多态性(RS4880)诱导成人急性淋巴细胞白血病患者肝毒性

获取原文
获取原文并翻译 | 示例
           

摘要

Asparaginase, which depletes asparagine and glutamine, activates amino-acid stress response. Oxidative stress mediated by excessive reactive oxygen species (ROS) causes enhanced mitochondrial permeabilization and subsequent cell apoptosis and is considered as a plausible mechanism for drug-induced hepatotoxicity, a common toxicity of asparaginase in adults with acute lymphoblastic leukemia (ALL). Studies investigating the pharmacogenetics of asparaginase in ALL are limited and focused on asparaginase-induced allergic reaction common in pediatric patients. Here, we sought to determine a potential association between the variant rs4880 in SOD2 gene, a key mitochondrial enzyme that protects cells against ROS, and hepatotoxicity during asparaginase-based therapy in 224 patients enrolled on CALGB-10102, a treatment trial for adults with ALL. We report that the CC genotype of rs4880 is associated with increased hepatotoxicity following asparaginase-based treatment. Thus, rs4880 likely contributes to asparaginase-induced hepatotoxicity, and functional studies investigating this single-nucleotide polymorphism (SNP) are needed to develop therapeutic approaches that mitigate this toxicity.
机译:脱氨酰胺和谷氨酰胺的天冬酰胺酶激活氨基酸应激反应。通过过量反应性氧(ROS)介导的氧化胁迫导致提高线粒体渗透性和随后的细胞凋亡,被认为是药物诱导的肝毒性的合理机制,具有急性淋巴细胞白血病(全部)的成年人中天冬酰胺酶的常见毒性。研究浅氨基氨基酶的药物生物的研究是有限的,并专注于儿科患者中常见的天冬氨酸酶诱导的过敏反应。在这里,我们寻求确定SOD2基因的变体RS4880之间的潜在关联,这是一种关键的线粒体酶,其保护细胞免受ROS的细胞和基于芦笋酶的治疗期间的肝毒性,在224名患者上注册CalgB-10102,为所有人进行了成人的治疗试验。我们认为RS4880的CC基因型与基于乙酰淀粉酶的治疗后的肝毒性增加有关。因此,RS4880可能有助于浅杀蛋白酶诱导的肝毒性,并且需要研究这种单核苷酸多态性(SNP)的功能性研究来开发减轻这种毒性的治疗方法。

著录项

  • 来源
    《The pharmacogenomics journal》 |2017年第3期|共6页
  • 作者单位

    Univ Southern Calif USC Sch Pharm Dept Pharm Los Angeles CA USA;

    Univ Chicago Dept Med Hematol Oncol Sect Chicago IL 60637 USA;

    Duke Canc Inst Alliance CALGB Stat Ctr Biostat Durham NC USA;

    Univ Chicago Dept Med Hematol Oncol Sect Chicago IL 60637 USA;

    Univ Chicago Dept Med Hematol Oncol Sect Chicago IL 60637 USA;

    Univ Chicago Dept Med Hematol Oncol Sect Chicago IL 60637 USA;

    Ohio State Univ Dept Med Div Hematol Columbus OH 43210 USA;

    City Hope Comprehens Canc Ctr Gehr Family Ctr Leukemia Dept Hematol &

    Hematopoiet Cell;

    Univ Chicago Dept Med Hematol Oncol Sect Chicago IL 60637 USA;

    Univ Chicago Dept Med Hematol Oncol Sect Chicago IL 60637 USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号